## Tyree H Kiser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1156289/publications.pdf

Version: 2024-02-01

230014 274796 2,478 123 27 44 citations h-index g-index papers 126 126 126 3186 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Correlation of antimicrobial fraction unbound and sieving coefficient in critically ill patients on continuous renal replacement therapy: a systematic review. Journal of Antimicrobial Chemotherapy, 2022, 77, 310-319.	1.3	3
2	Association Between Vasopressin Rebranding and Utilization in Patients With Septic Shock*. Critical Care Medicine, 2022, 50, 644-654.	0.4	13
3	Evaluation of Insulin Infusion Rates for the Treatment of Diabetic Ketoacidosis in the Emergency Department. Journal of Biosciences and Medicines, 2022, 10, 203-211.	0.1	0
4	700: CORRELATION OF ANTIMICROBIAL FRACTION UNBOUND AND CRRT SIEVING COEFFICIENT: A SYSTEMATIC REVIEW. Critical Care Medicine, 2022, 50, 344-344.	0.4	0
5	924: PHARMACODYNAMIC EVALUATION OF VARYING ALTEPLASE DOSAGES FOR THE TREATMENT OF PULMONARY EMBOLISM. Critical Care Medicine, 2022, 50, 459-459.	0.4	0
6	Pharmacokinetic Evaluation of Cefazolin in the Cerebrospinal Fluid of Critically III Patients. Open Forum Infectious Diseases, 2022, 9, ofab649.	0.4	10
7	Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. Clinical Pharmacokinetics, 2022, 61, 363-374.	1.6	17
8	Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2022, 54, 276-286.	1.0	10
9	Why So Salty? Transient Diabetes Insipidus After Discontinuation of Vasopressin., 2022, 1, .		0
10	Ribavirin and cellular ribavirinâ€triphosphate concentrations in blood and bronchoalveolar lavage fluid in two lung transplant patients with respiratory syncytial virus. Transplant Infectious Disease, 2021, 23, e13464.	0.7	1
11	Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110390.	0.7	14
12	Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. Journal of Thrombosis and Thrombolysis, 2021, 52, 517-522.	1.0	36
13	Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care. International Journal of Antimicrobial Agents, 2021, 57, 106310.	1.1	24
14	An overview of current and emerging antifungal pharmacotherapy for invasive fungal infections. Expert Opinion on Pharmacotherapy, 2021, 22, 1355-1371.	0.9	7
15	A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab. American Journal of Case Reports, 2021, 22, e931702.	0.3	10
16	Gender inequity and sexual harassment in the pharmacy profession: Evidence and call to action. American Journal of Health-System Pharmacy, 2021, 78, 2059-2076.	0.5	21
17	Principles of Kidney Pharmacotherapy for the Nephrologist: Core Curriculum 2021. American Journal of Kidney Diseases, 2021, 78, 442-458.	2.1	10
18	Impact of a <scp>pharmacistâ€inclusive postâ€discharge</scp> clinic on outcomes in heart failure patients with reduced ejection fraction: Rates of hospital readmission, emergency department visits, or death. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1516-1523.	0.5	3

#	Article	IF	Citations
19	Critical care essentials for pharmacy trainees and new clinical practitioners. American Journal of Health-System Pharmacy, 2021, 78, 1176-1183.	0.5	2
20	1134: Evaluation of Parenteral Lidocaine for Nephrolithiasis-Induced Renal Colic in the ED. Critical Care Medicine, 2021, 49, 569-569.	0.4	0
21	Gender inequity and sexual harassment in the pharmacy profession: Evidence and call to action executive summary. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1375-1378.	0.5	2
22	Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients. Journal of Thrombosis and Thrombolysis, 2020, 49, 259-267.	1.0	21
23	Cancer-associated thromboembolism: antithrombotic management of hospitalized patients. Journal of Thrombosis and Thrombolysis, 2020, 49, 59-66.	1.0	4
24	Noninvasive Ventilation Use in Critically Ill Patients with Acute Asthma Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1520-1530.	2.5	33
25	Hydroxocobalamin Versus Methylene Blue for Vasoplegic Syndrome in Cardiothoracic Surgery: A Retrospective Cohort. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 1763-1770.	0.6	20
26	Extrapolating Antifungal Animal Data to Humansâ€"Is It Reliable?. Current Fungal Infection Reports, 2020, 14, 50-62.	0.9	5
27	Azole-Resistant Aspergillus and Echinocandin-Resistant Candida: What Are the Treatment Options?. Current Fungal Infection Reports, 2020, 14, 141-152.	0.9	9
28	Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	8
29	Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin for the Treatment of Left Ventricular Thrombus. Journal of Cardiac Failure, 2019, 25, S26-S27.	0.7	10
30	Impact of Macrolide Antibiotics on Hospital Readmissions and Other Clinically Important Outcomes in Critically III Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Propensity Scoreâe "Matched Cohort Study. Pharmacotherapy, 2019, 39, 242-252.	1.2	10
31	Patterns of utilization and effects of hospital-specific factors on physical, occupational, and speech therapy for critically ill patients with acute respiratory failure in the USA: results of a 5-year sample. Critical Care, 2019, 23, 175.	2.5	12
32	Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center. Annals of Clinical Microbiology and Antimicrobials, 2019, 18, 13.	1.7	18
33	The Effectiveness of a Vancomycin Dosing Guideline in the Neonatal Intensive Care Unit for Achieving Goal Therapeutic Trough Concentrations. Journal of Clinical Pharmacology, 2019, 59, 997-1005.	1.0	23
34	Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961989661.	0.7	24
35	903. Critical Care Medicine, 2019, 47, 430.	0.4	3
36	Evaluation of Prophylactic Heparin Dosage Strategies and Risk Factors for Venous Thromboembolism in the Critically III Patient. Pharmacotherapy, 2019, 39, 232-241.	1.2	14

3

#	Article	IF	CITATIONS
37	997: NATIONAL SURVEY OF PHARMACY STUDENTS' OPINIONS OF CRITICAL CARE PHARMACISTS' ROLES/RESPONSIBILITIES. Critical Care Medicine, 2018, 46, 482-482.	0.4	O
38	921: EVALUATION OF UFH VERSUS LMWH FOR PHARMACOLOGIC THROMBOPROPHYLAXIS IN PATIENTS WITH CANCER. Critical Care Medicine, 2018, 46, 444-444.	0.4	0
39	660: EXTENDED-DURATION VERSUS STANDARD-DURATION OSELTAMIVIR IN CRITICALLY ILL PATIENTS WITH INFLUENZA. Critical Care Medicine, 2018, 46, 316-316.	0.4	16
40	African Americans Are Less Likely to Receive Care by a Cardiologist During anÂIntensive Care Unit Admission for HeartÂFailure. JACC: Heart Failure, 2018, 6, 413-420.	1.9	81
41	The authors reply. Critical Care Medicine, 2018, 46, e347-e348.	0.4	O
42	Antithrombin Administration During Intravenous Heparin Anticoagulation in the Intensive Care Unit: A Single-Center Matched Retrospective Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 145-150.	0.7	5
43	An Observational Study of the Efficacy of Cisatracurium Compared with Vecuronium in Patients with or at Risk for Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 897-904.	2.5	41
44	The authors reply. Critical Care Medicine, 2018, 46, e1224-e1225.	0.4	0
45	656: EVALUATION OF HIGH-DOSE VERSUS STANDARD-DOSE OSELTAMIVIR IN CRITICALLY ILL PATIENTS WITH INFLUENZA. Critical Care Medicine, 2018, 46, 314-314.	0.4	4
46	Divergent humoral responses to 23-valent pneumococcal polysaccharide vaccine in critically-ill burn and neurosurgical patients. PLoS ONE, 2018, 13, e0197037.	1.1	1
47	Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer. Journal of Thrombosis and Haemostasis, 2018, 16, 2492-2500.	1.9	10
48	Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism*. Critical Care Medicine, 2018, 46, 1617-1625.	0.4	71
49	Calcineurin Inhibitor and Nonsteroidal Antiâ€inflammatory Drug Interaction: Implications of Changes in Renal Function Associated With Concurrent Use. Journal of Clinical Pharmacology, 2018, 58, 1443-1451.	1.0	12
50	Patient nonadherence to filling discharge medication prescriptions from the emergency department: Barriers and clinical implications. American Journal of Health-System Pharmacy, 2018, 75, 316-320.	0.5	13
51	A Randomized Pharmacokinetic and Pharmacodynamic Evaluation of Every 8â€Hour and 12â€Hour Dosing Strategies of Vancomycin and Cefepime in Neurocritically ill Patients. Pharmacotherapy, 2018, 38, 921-934.	1.2	12
52	Evaluation of Systemic Corticosteroids in Patients With an Acute Exacerbation of COPD and a Diagnosis of Pneumonia. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2018, 5, 57-65.	0.5	9
53	Five years of lesson modification to implement non-traditional learning sessions in a traditional-delivery curriculum: A retrospective assessment using applied implementation variables. Currents in Pharmacy Teaching and Learning, 2017, 9, 237-245.	0.4	1
54	Perceived Motivating Factors and Barriers for the Completion of Postgraduate Training Among American Pharmacy Students Prior to Beginning Advanced Pharmacy Practice Experiences. American Journal of Pharmaceutical Education, 2017, 81, 90.	0.7	28

#	Article	IF	CITATIONS
55	Outcomes of ICU Patients With a Discharge Diagnosis of Critical Illness Polyneuromyopathy: A Propensity-Matched Analysis. Critical Care Medicine, 2017, 45, 2055-2060.	0.4	39
56	Extended Stability of Epinephrine Hydrochloride Injection in Polyvinyl Chloride Bags Stored in Amber Ultraviolet Light–Blocking Bags. Hospital Pharmacy, 2017, 52, 570-573.	0.4	3
57	Thiocyanate Accumulation in Critically Ill Patients Receiving Nitroprusside Infusions. Journal of Intensive Care Medicine, 2017, 32, 547-553.	1.3	5
58	Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Annals of Clinical Microbiology and Antimicrobials, 2017, 16, 60.	1.7	54
59	Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration. American Journal of Case Reports, 2017, 18, 458-462.	0.3	13
60	A Survey of Corticosteroid Dosing for Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Assisted Ventilation. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2017, 4, 186-193.	0.5	4
61	Evaluation of Early Dexmedetomidine Addition to the Standard of Care for Severe Alcohol Withdrawal in the ICU. Journal of Intensive Care Medicine, 2016, 31, 198-204.	1.3	31
62	Management of intracerebral hemorrhage & Darbing and Statins of Statins. Vascular Health and Risk Management, 2016, 12, 153.	1.0	16
63	Stability of dronabinol capsules when stored frozen, refrigerated, or at room temperature. American Journal of Health-System Pharmacy, 2016, 73, 1088-1092.	0.5	6
64	Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 423-428.	0.7	52
65	Use of a Cholestyramine Washout in a Patient With Septic Shock on Leflunomide Therapy. Journal of Intensive Care Medicine, 2016, 31, 412-414.	1.3	11
66	High-Dose Versus Low-Dose Systemic Steroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Systematic Review. Chronic Obstructive Pulmonary Diseases (Miami,) Tj ETQq0	0 00:gBT/	Ov <b>e</b> rlock 10 T
67	Pharmacist and Physician Collaborative Practice Model Improves Vancomycin Dosing in an Intensive Care Unit. International Journal of Clinical Medicine, 2016, 07, 675-684.	0.1	5
68	Stability of Ribavirin for Inhalation Packaged in Syringes or Glass Vials when Stored Frozen, Refrigerated, and at Room Temperature. International Journal of Pharmaceutical Compounding, 2016, 20, 521-525.	0.0	1
69	Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events. Expert Opinion on Drug Safety, 2015, 14, 269-280.	1.0	14
70	A Randomized, Double-Blind Pilot Study of Dexmedetomidine Versus Midazolam for Intensive Care Unit Sedation. Journal of Intensive Care Medicine, 2015, 30, 167-175.	1.3	41
71	Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. Clinical Pharmacokinetics, 2015, 54, 783-795.	1.6	107
72	Evaluation of sulfobutylether- $\hat{l}^2$ -cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Critical Care, 2015, 19, 32.	2.5	72

#	Article	IF	CITATIONS
73	Severe acute exacerbations of chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2015, 21, 142-148.	1.2	12
74	Research Fellowship Programs as a Pathway for Training Independent Clinical Pharmacy Scientists. Pharmacotherapy, 2015, 35, e13-e19.	1.2	12
75	Evaluation of Sulfobutylether- $\hat{l}^2$ -Cyclodextrin Exposure in a Critically III Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration. Antimicrobial Agents and Chemotherapy, 2015, 59, 6653-6656.	1.4	12
76	Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients. Journal of Critical Care, 2015, 30, 1153.e1-1153.e6.	1.0	18
77	Cerebral Vasospasm in Critically III Patients with Aneurysmal Subarachnoid Hemorrhage: Does the Evidence Support the Ever-Growing List of Potential Pharmacotherapy Interventions?. Hospital Pharmacy, 2014, 49, 923-941.	0.4	15
78	Evaluation of Phenylephrine Stability in Polyvinyl Chloride Bags. Hospital Pharmacy, 2014, 49, 455-457.	0.4	6
79	A Randomized, Double-Blind, Placebo-Controlled Dose Range Study of Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal*. Critical Care Medicine, 2014, 42, 1131-1139.	0.4	94
80	Antithrombotic Therapy in Patients With Thrombocytopenic Cancer. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 799-806.	0.7	20
81	A survey of prescriber perceptions about the prevention of stress-related mucosal bleeding in the intensive care unit. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 658-662.	0.7	15
82	Weight-based versus set dosing of vancomycin for coronary artery bypass grafting or aortic valve surgery. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1925-1930.	0.4	13
83	Outcomes Associated with Corticosteroid Dosage in Critically Ill Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1052-1064.	2.5	72
84	Management of Extravasation Injuries: A Focused Evaluation of Noncytotoxic Medications. Pharmacotherapy, 2014, 34, 617-632.	1.2	113
85	The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clinical Transplantation, 2014, 28, 590-597.	0.8	20
86	Comparison of the aPTT With Alternative Tests for Monitoring Direct Thrombin Inhibitors in Patient Samples. American Journal of Clinical Pathology, 2014, 141, 665-674.	0.4	45
87	Hepatorenal Syndrome. International Journal of Clinical Medicine, 2014, 05, 102-110.	0.1	1
88	Correlation of Pharmacokinetic/Pharmacodynamic–Derived Predictions of Antibiotic Efficacy with Clinical Outcomes in Severely III Patients with <i>Pseudomonas aeruginosa</i> Pneumonia. Pharmacotherapy, 2013, 33, 1022-1034.	1.2	8
89	The CYP3A Enzyme Inhibitor Diltiazem, Rather Than Genetic Polymorphisms, Is Associated with Everolimus Concentrations in Lung Transplant Recipients. Journal of Heart and Lung Transplantation, 2013, 32, S295-S296.	0.3	0
90	Pharmacologic Options for Prevention and Management of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage. Hospital Pharmacy, 2013, 48, S2-S9.	0.4	2

#	Article	lF	Citations
91	425. Critical Care Medicine, 2013, 41, A102-A103.	0.4	1
92	732. Critical Care Medicine, 2013, 41, A181.	0.4	1
93	Pharmacologic Options for Prevention and Management of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage. Hospital Pharmacy, 2013, 48, S2-S9.	0.4	1
94	Intraventricular Daptomycin and Intravenous Linezolid for the Treatment of External Ventricular-Drain–Associated Ventriculitis Due to Vancomycin-Resistant Enterococcus faecium. Annals of Pharmacotherapy, 2012, 46, 1722-1722.	0.9	33
95	Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. Journal of Heart and Lung Transplantation, 2012, 31, 159-166.	0.3	15
96	Managing the Intravenous Calcium Shortage: Evaluation of Calcium Chloride Stability in 0.9% Sodium Chloride and Dextrose 5% Water Polyvinyl Chloride Bags. Hospital Pharmacy, 2012, 47, 27-30.	0.4	2
97	Key Articles and Guidelines in the Management of Pulmonary Arterial Hypertension: 2011 Update. Pharmacotherapy, 2012, 32, e134-e169.	1.2	2
98	935. Critical Care Medicine, 2012, 40, 1-328.	0.4	1
99	Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans. Current Fungal Infection Reports, 2011, 5, 59-66.	0.9	1
100	Evaluation of empiric versus nomogramâ€based direct thrombin inhibitor management in patients with suspected heparinâ€induced thrombocytopenia. American Journal of Hematology, 2011, 86, 267-272.	2.0	25
101	Neuromuscular Blockade Resistance During Therapeutic Hypothermia. Annals of Pharmacotherapy, 2011, 45, 418-418.	0.9	10
102	Bivalirudin versus Unfractionated Heparin for Prevention of Hemofilter Occlusion During Continuous Renal Replacement Therapy. Pharmacotherapy, 2010, 30, 1117-1126.	1.2	23
103	Efflux Pump Contribution to Multidrug Resistance in Clinical Isolates of <i>Pseudomonas aeruginosa</i> . Pharmacotherapy, 2010, 30, 632-638.	1.2	28
104	Reliability and accuracy of practitioner-calculated Acute Physiology and Chronic Health Evaluation II scores for determining the appropriateness of drotrecogin alfa (activated). American Journal of Health-System Pharmacy, 2010, 67, 136-143.	0.5	2
105	Systemic Anticoagulation Considerations in Chronic Kidney Disease. Advances in Chronic Kidney Disease, 2010, 17, 420-427.	0.6	51
106	Prefilter Bivalirudin for Preventing Hemofilter Occlusion in Continuous Renal Replacement Therapy. Annals of Pharmacotherapy, 2009, 43, 1360-1365.	0.9	7
107	Treatment of Hepatorenal Syndrome. Pharmacotherapy, 2009, 29, 1196-1211.	1.2	25
108	Proposed Revision to the Existing Specialty and Specialist Certification Framework for Pharmacy Practitioners. Pharmacotherapy, 2009, 29, 489-489.	1.2	17

#	Article	IF	CITATIONS
109	Propylene Glycol Accumulation in Critically III Patients Receiving Continuous Intravenous Lorazepam Infusions. Annals of Pharmacotherapy, 2009, 43, 1964-1971.	0.9	50
110	Safety, Efficacy, and Dosing Requirements of Bivalirudin in Patients with Heparin-Induced Thrombocytopenia. Pharmacotherapy, 2008, 28, 1115-1124.	1.2	71
111	Erythromycin vs Metoclopramide for Facilitating Gastric Emptying and Tolerance to Intragastric Nutrition in Critically Ill Patients. Journal of Parenteral and Enteral Nutrition, 2008, 32, 412-419.	1.3	90
112	Gastric Motility Function in Critically Ill Patients TolerantvsIntolerant to Gastric Nutrition. Journal of Parenteral and Enteral Nutrition, 2008, 32, 45-50.	1.3	72
113	Stability of phenylephrine hydrochloride injection in polypropylene syringes. American Journal of Health-System Pharmacy, 2007, 64, 1092-1095.	0.5	8
114	Stability of acetylcysteine solution repackaged in oral syringes and associated cost savings. American Journal of Health-System Pharmacy, 2007, 64, 762-766.	0.5	10
115	Adjunctive Dexmedetomidine Therapy in the Intensive Care Unit: A Retrospective Assessment of Impact on Sedative and Analgesic Requirements, Levels of Sedation and Analgesia, and Ventilatory and Hemodynamic Parameters. Pharmacotherapy, 2007, 27, 351-359.	1.2	35
116	Evaluation of Bivalirudin Treatment for Heparin-Induced Thrombocytopenia in Critically Ill Patients with Hepatic and/or Renal Dysfunction. Pharmacotherapy, 2006, 26, 452-460.	1.2	82
117	Levofloxacin Pharmacokinetics and Pharmacodynamics in Patients with Severe Burn Injury. Antimicrobial Agents and Chemotherapy, 2006, 50, 1937-1945.	1.4	39
118	Formulary Substitution of Proton Pump Inhibitors Based on Acquisition Price: Changes in Usage and Costs of Acid-Suppressant Therapies. P and T, 2006, 31, 716-734.	1.0	0
119	Evaluation of Diagnostic Tests and Argatroban or Lepirudin Therapy in Patients with Suspected Heparin-Induced Thrombocytopenia. Pharmacotherapy, 2005, 25, 1736-1745.	1.2	43
120	Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrology Dialysis Transplantation, 2005, 20, 1813-1820.	0.4	75
121	EVALUATION OF LEVOFLOXACIN PHARMACOKINETICS IN PATIENTS WITH SEVERE BURN INJURY Critical Care Medicine, 2005, 33, A172.	0.4	0
122	ERYTHROMYCIN VS. METOCLOPRAMIDE FOR FACILITATING GASTRIC EMPTYING AND TOLERANCE TO INTRAGASTRIC NUTRITION Critical Care Medicine, 2005, 33, A97.	0.4	0
123	Correlation Between and Nursing Satisfaction With CIWA-Ar, mMINDS, and SEWS Scoring Tools for the Assessment of Severe Alcohol Withdrawal Syndrome in ICU Patients. Annals of Pharmacotherapy, 0, , 106002802211025.	0.9	0